
Glanbia plc
GLAPYOTCConsumer Defensive● Active
$131.99
+$0.98(+0.75%)
Market Cap$6.4B
P/E Ratio—
52W High$131.99
52W Low$71
Glanbia plc(GLAPY)· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · GLAPY · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.96B | $3.98B | $5.97B | $5.55B | $4.20B |
| Cost of Revenue | $2.97B | $2.77B | $4.73B | $4.60B | $3.37B |
| Gross Profit | $0.99B | $1.21B | $1.24B | $0.95B | $0.83B |
| Gross Margin %(computed) | 24.99% | 30.35% | 20.72% | 17.20% | 19.79% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.03B | $0.03B |
| G&A Expenses | $0.00B | $0.27B | $0.20B | $0.21B | $0.23B |
| Total Operating Expenses | $0.64B | $0.96B | $0.80B | $0.74B | $0.67B |
| Operating Income | $0.35B | $0.24B | $0.43B | $0.22B | $0.16B |
| Operating Margin %(computed) | 8.90% | 6.11% | 7.23% | 3.96% | 3.77% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.03B | $0.02B | $0.02B | $0.02B |
| Income Before Tax | $0.21B | $0.22B | $0.43B | $0.22B | $0.16B |
| Income Tax Expense | $0.03B | $0.04B | $0.05B | $0.03B | $0.02B |
| Net Income | $0.18B | $0.17B | $0.34B | $0.25B | $0.19B |
| Net Margin %(computed) | 4.64% | 4.29% | 5.75% | 4.57% | 4.51% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.65 | $3.20 | $7.10 | $3.40 | $2.40 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.06B | 0.06B |
| EBITDA | $0.50B | $0.35B | $0.62B | $0.36B | $0.29B |
| EBITDA Margin %(computed) | 12.67% | 8.76% | 10.33% | 6.50% | 6.93% |
数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · USD · B
深入了解Glanbia plc
关于Glanbia plc(GLAPY)损益表
Glanbia plc(GLAPY)损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年,GLAPY实现营收$3.96B,毛利润$0.99B(毛利率24.99%),净利润$0.18B(净利率4.64%)。
常见问题
GLAPY · 4 问Glanbia plc(GLAPY)2025财年营收为$3.96B,同比down0.5%。
GLAPY revenueGLAPY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08